Nakamura Junzo, Kobayashi Kazuko, Fumoto Shintaro, Nishi Junya, Mukai Takahiro, Nakashima Mikiro, Sasaki Hitoshi, Nishida Koyo
Graduate School of Biomedical Sciences, Nagasaki University, Japan.
Biol Pharm Bull. 2005 Jun;28(6):1049-53. doi: 10.1248/bpb.28.1049.
The present study was undertaken to elucidate the stomach- and site-selective delivery of 5-fluorouracil (5-FU) following its application on the gastric serosal surface in rats. An experimental system utilizing a cylindrical diffusion cell attached to the gastric serosal surface was established. To evaluate the gastric distribution of 5-FU, the stomach was separated into the site under the diffusion cell (site 1) and the site not under the diffusion cell (site 2). Furthermore, the mucosal side at site 1 was separated from the serosal side. After intravenous and oral administration of 5-FU, the 5-FU concentrations at sites 1 and 2 until 240 min were similar. After gastric serosal surface application of 5-FU, however, the concentration of 5-FU at site 1 until 240 min was approximately 10-fold higher than that at site 2, and was sustained. Furthermore, the 5-FU concentration on the mucosal side at site 1 and the serosal side at site 1 were comparable after gastric serosal surface application. The blood concentration of 5-FU was low (<4.4 microg/ml) until 240 min after gastric serosal surface application. The maximum blood concentration of 5-FU after gastric serosal surface application was significantly lower than after intravenous administration. Thus, the stomach- and site-selective delivery system following application on the gastric serosal surface could be applied with anticancer drugs for the treatment of gastric cancer.
本研究旨在阐明5-氟尿嘧啶(5-FU)在大鼠胃浆膜表面应用后的胃和部位选择性递送情况。建立了一种利用附着于胃浆膜表面的圆柱形扩散池的实验系统。为了评估5-FU在胃内的分布,将胃分为扩散池下方的部位(部位1)和不在扩散池下方的部位(部位2)。此外,部位1的黏膜侧与浆膜侧分开。静脉内和口服给予5-FU后,部位1和部位2在240分钟内的5-FU浓度相似。然而,在胃浆膜表面应用5-FU后,部位1在240分钟内的5-FU浓度比部位2高约10倍,且持续存在。此外,胃浆膜表面应用后,部位1黏膜侧和部位1浆膜侧的5-FU浓度相当。胃浆膜表面应用后240分钟内,5-FU的血药浓度较低(<4.4微克/毫升)。胃浆膜表面应用后5-FU的最大血药浓度明显低于静脉给药后。因此,在胃浆膜表面应用后的胃和部位选择性递送系统可与抗癌药物一起用于治疗胃癌。